Alnylam Pharmaceuticals Inc. [ALNY] moved up 49.33: Why It’s Important


Alnylam Pharmaceuticals Inc. [NASDAQ: ALNY] gained 49.33% on the last trading session, reaching $212.01 price per share at the time. The company report on August 3, 2022 that Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


– Patisiran Met the Primary Endpoint with a Statistically Significant Improvement in 6-Minute Walk Test Compared to Placebo at 12 Months –.

– Patisiran Also Met the First Secondary Endpoint with a Statistically Significant Improvement in Quality of Life, as Measured by the Kansas City Cardiomyopathy Questionnaire, Compared to Placebo at 12 Months –.

Alnylam Pharmaceuticals Inc. represents 120.90 million in outstanding shares, while the company has a total market value of $25.60 billion with the latest information. ALNY stock price has been found in the range of $198.00 to $220.92.

If compared to the average trading volume of 802.26K shares, ALNY reached a trading volume of 8548314 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Alnylam Pharmaceuticals Inc. [ALNY]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALNY shares is $203.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALNY stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cantor Fitzgerald have made an estimate for Alnylam Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on July 13, 2022. The new note on the price target was released on June 27, 2022, representing the official price target for Alnylam Pharmaceuticals Inc. stock. On April 25, 2022, analysts decreased their price target for ALNY shares from 210 to 178.

The Average True Range (ATR) for Alnylam Pharmaceuticals Inc. is set at 10.72, with the Price to Sales ratio for ALNY stock in the period of the last 12 months amounting to 28.95. The Price to Book ratio for the last quarter was 145.21, with the Price to Cash per share for the same quarter was set at 17.48.

Trading performance analysis for ALNY stock

Alnylam Pharmaceuticals Inc. [ALNY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 49.33. With this latest performance, ALNY shares gained by 40.66% in over the last four-week period, additionally plugging by 46.28% over the last 6 months – not to mention a rise of 18.57% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALNY stock in for the last two-week period is set at 83.61, with the RSI for the last a single of trading hit 88.83, and the three-weeks RSI is set at 78.75 for Alnylam Pharmaceuticals Inc. [ALNY]. The present Moving Average for the last 50 days of trading for this stock 140.84, while it was recorded at 155.90 for the last single week of trading, and 156.59 for the last 200 days.

Alnylam Pharmaceuticals Inc. [ALNY]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Alnylam Pharmaceuticals Inc. [ALNY] shares currently have an operating margin of -83.93 and a Gross Margin at +83.40. Alnylam Pharmaceuticals Inc.’s Net Margin is presently recorded at -101.01.

Return on Equity for this stock declined to -106.31, with Return on Assets sitting at -24.19.

Alnylam Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.60 and a Current Ratio set at 3.80.

Alnylam Pharmaceuticals Inc. [ALNY]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALNY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Alnylam Pharmaceuticals Inc. go to 7.86%.

An analysis of insider ownership at Alnylam Pharmaceuticals Inc. [ALNY]

There are presently around $24,128 million, or 98.40% of ALNY stock, in the hands of institutional investors. The top three institutional holders of ALNY stocks are: FMR LLC with ownership of 16,045,316, which is approximately -10.561% of the company’s market cap and around 0.51% of the total institutional ownership; VANGUARD GROUP INC, holding 10,829,144 shares of the stock with an approximate value of $2.3 billion in ALNY stocks shares; and BAILLIE GIFFORD & CO, currently with $2.15 billion in ALNY stock with ownership of nearly -4.493% of the company’s market capitalization.

Positions in Alnylam Pharmaceuticals Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 212 institutional holders increased their position in Alnylam Pharmaceuticals Inc. [NASDAQ:ALNY] by around 10,862,615 shares. Additionally, 210 investors decreased positions by around 8,521,205 shares, while 68 investors held positions by with 94,423,195 shares. The mentioned changes placed institutional holdings at 113,807,015 shares, according to the latest SEC report filing. ALNY stock had 66 new institutional investments in for a total of 1,511,197 shares, while 61 institutional investors sold positions of 2,049,809 shares during the same period.